The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesFlow Cyt: Use 0.5µg for 106 cells in 100µl volume.
IHC-P: Use at an assay dependent dilution.
IP: Use at an assay dependent dilution.
WB: Use at an assay dependent dilution. Predicted molecular weight: 13 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionEnhances the phosphorylation and activation of AKT1, AKT2 and AKT3. Promotes nuclear translocation of AKT1. Enhances cell proliferation, stabilizes mitochondrial membrane potential and promotes cell survival.
Tissue specificityRestricted in the T-cell lineage to immature thymocytes and activated peripheral lymphocytes. Preferentially expressed early in T- and B-lymphocyte differentiation.
Involvement in diseaseNote=Chromosomal aberrations activating TCL1A are found in chronic T-cell leukemias (T-CLL). Translocation t(14;14)(q11;q32); translocation t(7;14)(q35;q32); inversion inv(14)(q11;q32) that involves the T-cell receptor alpha/delta loci.
Staining of Daudi cells with ab91211 at 0.25 µg (blue histogram), or purified Mouse IgG2b, isotype control at 0.25 µg (green histogram), followed by treatment with Biotin anti-Mouse IgG and Phycoerythrin (PE) Streptavidin. Total viable cells were used for analysis.
References for Anti-Tcl1 antibody [1-21] (ab91211)
has not yet been referenced specifically in any publications.
Publishing research using ab91211? Please let us know so that we can cite the reference in this datasheet.
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"